Drug Trial Radar · NCT07226661
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Dec 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
Conditions
- Major Depressive Disorder (MDD)
Interventions
SPN-821 2400 mgDrug
SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling
PlaceboDrug
Matched placebo oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.Time frame: 4 weeks
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Recruiting
IMA Clinical Research Phoenix
Phoenix, Arizona · Recruiting
Woodland Research Northwest (ERG)
Rogers, Arkansas · Recruiting
Inland Psychiatric Medical Group
Chino, California · Recruiting
Leading Edge Research (Eximia Network)
Encino, California · Recruiting
Cenexel Collaborative Neuroscience Network
Garden Grove, California · Recruiting
Synergy Research (ERG Network)
Lemon Grove, California · Recruiting
Catalina Research Institute (Elixia)
Montclair, California · Recruiting
ATP Clinical Research
Orange, California · Recruiting
NRC Research Institute
Orange, California · Recruiting
Lumos Clinical Research Center
San Jose, California · Recruiting
Inland Psychiatric Medical Group
Temecula, California · Recruiting
Mountain View Clinical Research
Denver, Colorado · Recruiting
CT Clinical Research
Cromwell, Connecticut · Recruiting
CNS Healthcare - Jacksonville
Jacksonville, Florida · Recruiting
Avantis Clinical Research
Miami, Florida · Recruiting
CNS Healthcare of Orlando
Orlando, Florida · Recruiting
Space Coast Neuropsychiatric Research Institute
Palm Bay, Florida · Recruiting
Cenexel Tampa
Tampa, Florida · Recruiting
Interventional Psychiatry of Tampa Bay
Tampa, Florida · Recruiting
Cenexel Atlanta (ACMR)
Atlanta, Georgia · Recruiting
Cenexel iResearch Atlanta
Decatur, Georgia · Recruiting
AMR Conventions Research
Warrenville, Illinois · Recruiting
Precise Clinical Research
Flowood, Mississippi · Recruiting
Psychiatric Care and Research Center
O'Fallon, Missouri · Recruiting
Midwest Research Group
Saint Charles, Missouri · Recruiting
Vector Clinical Trials
Las Vegas, Nevada · Recruiting
Cenexel Marlton (HRI)
Marlton, New Jersey · Recruiting
SPRI Clinical Trials
Brooklyn, New York · Recruiting
Manhattan Behavioral Medicine
New York, New York · Recruiting
New Hope Clinical Research
Charlotte, North Carolina · Recruiting
Paradigm Research Professionals
Oklahoma City, Oklahoma · Recruiting
Summit Headlands (Headlands Research)
Portland, Oregon · Recruiting
Houston Clinical Trials
Bellaire, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
DM Clinical
Houston, Texas · Recruiting
Grayline Research Center
Wichita Falls, Texas · Recruiting
Alpine Research Organization
Clinton, Utah · Recruiting
Aura Wellness
Salt Lake City, Utah · Recruiting
Core Clinical Research
Everett, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.